Last reviewed · How we verify
NCT03129451
The Microbiome in Parkinson's Disease
trial testing Microbiome specimens in stool in Parkinson Disease in 23 participants. Completed in 7 January 2021.
7 January 2021
Quick facts
| Lead sponsor | Corewell Health West |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 23 |
| Start date | 17 April 2017 |
| Primary completion | 7 January 2021 |
| Estimated completion | 7 January 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Microbiome specimens in stool
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Corewell Health West — full company profile →
Who can join
Eligibility, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To investigate the dynamic relationship between the intestinal microbiota and Inflammation in subjects with Parkinson's disease.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Nutraceuticals: An integrative approach to starve Parkinson's disease.
Lama A, Pirozzi C, Avagliano C, Annunziata C, et al · · 2020 · cited 16× · PMID 34589828 · DOI 10.1016/j.bbih.2020.100037 -
From the Gut to the Brain: Is Microbiota a New Paradigm in Parkinson's Disease Treatment?
Vilela C, Araújo B, Soares-Guedes C, Caridade-Silva R, et al · · 2024 · cited 7× · PMID 38727306 · DOI 10.3390/cells13090770
Verify or expand the search:
- PubMed search for NCT03129451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Corewell Health West trials
Trials by the same sponsor.
- NCT07459504 — SMART Diets for MASLD · Phase 2 · not yet recruiting
- NCT07170020 — Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections · NA · not yet recruiting
- NCT07076082 — Vascular Trial Associated Registry Pilot · Phase 4 · recruiting
- NCT07100483 — Comparing Surgical Management Methods of Atrial Fibrillation · NA · enrolling by invitation
- NCT06422273 — Protest Trial: TXA vs Saline · Phase 3 · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03129451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Corewell Health West
- Last refreshed: 8 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03129451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing